I can't even find that line? Where is that. I think you've found one line to suit your narrative. what about 'Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement from baseline that was statistically significant (Wilcoxon signed rank test p<0.05) and considered clinically meaningful. The mean improvement from baseline was statistically significant, whether calculated for the subjects that completed dosing (mITT population), or including discontinued subjects (ITT population). Improvements were seen in clinically important aspects of Angelman syndrome, including communication, behavior, cognition and motor abilities.'
- Forums
- ASX - By Stock
- Ann: Phase 2 trial shows significant improvements in Angelman
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.56%
!
$14.28

I can't even find that line? Where is that. I think you've found...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.28 |
Change
0.080(0.56%) |
Mkt cap ! $1.777B |
Open | High | Low | Value | Volume |
$14.22 | $14.55 | $14.10 | $4.611M | 320.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6352 | $14.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.38 | 4000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2012 | 14.070 |
1 | 740 | 14.060 |
2 | 437 | 14.000 |
1 | 2000 | 13.920 |
1 | 720 | 13.880 |
Price($) | Vol. | No. |
---|---|---|
14.380 | 4000 | 1 |
14.400 | 3000 | 1 |
14.450 | 9123 | 1 |
14.500 | 200 | 1 |
14.580 | 3131 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online